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ABSTRACT: Healthcare-associated infections pose a serious risk
for patients, staﬀ, and visitors and are a severe burden on the
National Health Service, costing at least £1 billion annually.
Antimicrobial surfaces signiﬁcantly contribute toward reducing the
incidence of infections as they prevent bacterial adhesion and cause
bacterial cell death. Using a simple, easily upscalable swell−
encapsulation−shrink method, novel antimicrobial surfaces have
been developed by incorporating metal oxide nanoparticles (NPs) and crystal violet (CV) dye into medical-grade polyurethane
sheets. This study compares the bactericidal eﬀects of polyurethane incorporating ZnO, Mg-doped ZnO, and MgO. All metal
oxide NPs are well deﬁned, with average diameters ranging from 2 to 18 nm. These materials demonstrate potent bactericidal
activity when tested against clinically relevant bacteria such as Escherichia coli and Staphylococcus aureus. Additionally, these
composites are tested against an epidemic strain of methicillin-resistant Staphylococcus aureus (MRSA) that is rife in hospitals
throughout the UK. Furthermore, we have tested these materials using a low light intensity (∼500 lx), similar to that present in
many clinical environments. The highest activity is achieved from polymer composites incorporating CV and ∼3 nm ZnO NPs,
and the diﬀerent performances of the metal oxides have been discussed.
1. INTRODUCTION
Healthcare-associated infections (HCAIs) aﬀect millions of
patients worldwide, resulting in signiﬁcant mortality and
economic impact. This burden continues to grow as
increasingly susceptible patients, such as the elderly or those
suﬀering from chronic conditions, become more common.1−3 It
has been estimated that eﬀective new antimicrobials used in
combination with improved health/safety good practice could
prevent an estimated 15−30% of HCAIs in the United
Kingdom.3,4 The development of such self-sterilizing surfaces
in hospitals could sustainably reduce the HCAI rates over time
by eliminating the transfer of bacteria that would usually occur
from contact among patients, healthcare workers, and
contaminated hospital surfaces.5 One preventative strategy is
to produce antimicrobial coatings that can kill the bacteria by
continually delivering active compounds to the environment.6
Such products include microbiocide-releasing surfaces and
metal-coated surfaces (e.g., silver and copper).5
An alternative method for disinfecting surfaces is by coating
them with light-activated antimicrobial agents, such as photo-
sensitizers, which destroy bacteria via the production of reactive
oxygen species (ROS) using photodynamic therapy (PDT).7
Unlike other antimicrobials, radical species have nonspeciﬁc
targets within a microbe, decreasing the likelihood of
developing resistance.8,9 Upon light activation, the photo-
sensitizer molecules in their ground state are promoted to the
lowest energy excited singlet state and can then undergo
intersystem crossing to a longer-lived excited triplet state, which
mediates the generation of cytotoxic ROS via type I or type II
mechanistic pathways.7 Type I involves the activated photo-
sensitizer reacting directly with the substrate or molecule to
form radicals, and type II involves the formation of singlet
oxygen from ground-state molecular oxygen via the triplet
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state.9 Common photosensitizers used to destroy cancerous
tissues include Rose Bengal,10,11 methylene blue,8,12−16 and
crystal violet (CV).17−22 These photosensitizers can be coated
onto polymers, and upon light activation, they generate ROS,
causing oxidative damage and cell death.21 We have previously
reported a detailed description of the photochemical
mechanisms involved in PDT.20
Dye-coated polymeric surfaces have shown signiﬁcant
enhancement of bactericidal activity when combined with
various nanoparticles (NPs)8,9,15,20−22 that display antibacterial
properties relative to the bulk phase due to an increased surface
area, leading to a greater particle surface reactivity.23 ZnO NPs
with antibacterial activity have received much interest for
biomedical applications, as studies have shown them to have
selective toxicity toward bacteria but minimal eﬀects on
mammalian cells.20 The proposed mechanism of their
antimicrobial activity is through photo-oxidative stress induced
by ROS generation,24 similar to the mechanism of photo-
sensitizers. There have been various studies on the eﬃcacious
bactericidal eﬀects of MgO,25−29 and similar to ZnO, its
advantages include aﬀordability and biocompatibility. Proper-
ties such as size, morphology, concentration, and defects30 can
aﬀect the antibacterial activity of NPs, for example, smaller
sized NPs possess better antimicrobial action.31
It is well established in the literature that doping into ZnO
host matrices can enhance their antibacterial activity by tuning
their optical and electrical properties.32−34 Zhang et al. reported
that doping ZnO with Ag increased the antibacterial activity of
ZnO,30 and many studies have shown similar eﬀects by doping
ZnO with Sn,35 Co,33 and Mn.34,36 Mg2+ ions are readily
incorporated into the ZnO lattice by substitution due to the
similar ionic radii of Mg2+ and Zn2+.37 It is reported that doping
ZnO with Mg can change its electronic and luminescent
properties, surface morphology, and defect density.38 The
surface (defect) structure is of particular interest with respect to
the generation of ROS; therefore, investigating the eﬀects of
dopants on antibacterial activity is of interest.
In a previous study by our group, ∼18 nm ZnO NPs were
synthesized via thermal decomposition of zinc oleate and
encapsulated into medical-grade polyurethane squares that
were coated with CV dye.20 At a visible light intensity of ∼6600
lx, these samples were highly eﬀective at reducing the numbers
of Escherichia coli within 4 h and Staphylococcus aureus within
only 1 h by ≥4 log. Such potent antibacterial activity was also
observed against both the bacteria in the dark using the
combination of CV and ZnO, demonstrating that a synergistic
eﬀect is responsible for the increased antibacterial activity
shown by the dye and NP together.
In this article, we report the preparation of 15−18 nm sized
Mg-doped ZnO (ZnMgO; 10% Mg) and MgO NPs capped
with oleic acid (OA). These NPs are swell-encapsulated into
CV-coated polyurethane, and their antibacterial activities are
assessed in the dark and after exposure to visible light.20
Alongside these larger NPs, we synthesized 2−4 nm sized
di(octyl) phosphinic acid (DOPA)-capped ZnO and ZnMgO
NPs (10% Mg), which were also incorporated with CV and
encapsulated into polyurethane for antibacterial activity. For
these samples incorporating smaller NPs, we used a much
lower light intensity than that in the previous work (∼500 lx),
as this is the level typically present in the clinical areas of a
London teaching hospital (Prof. P. Wilson, personal
communication). To further increase the relevance of our
work to healthcare environments, we tested the bactericidal
activity of our novel, biocompatible materials using an epidemic
strain of methicillin-resistant S. aureus (EMRSA-16), one of two
clones known to predominate in the United Kingdom (PHE).
We hypothesized that the light-induced bactericidal activity of
ZnO NPs in combination with CV will depend on the NP size
and doping with Mg. Therefore, the primary aim of this study
was to investigate whether the bactericidal activity of ZnO NPs
is aﬀected by the diameter, with and without Mg doping, using
two diﬀerent methods for preparing small doped ZnO NPs
with diameters as small as 2 nm. We also examined the eﬀect of
the capping ligand on the antibacterial eﬃcacy. Whereas we
demonstrated that smaller ZnO NPs exhibit a higher
bactericidal activity even without a photosensitizer, doping
with Mg elicited no signiﬁcant enhancement in the antibacterial
activity of ZnO.
2. EXPERIMENTAL SECTION
2.1. Chemicals and Substrates. All chemicals and
reagents described in the NP synthesis and material preparation
were purchased from Sigma-Aldrich Chemical Co. except for
toluene (Fischer Scientiﬁc, UK) and dichloromethane (DCM)
(VWR, UK). Deionized water (resistivity 15 MΩ cm) was used
in all synthetic work, and the substrate was medical-grade ﬂat
polyurethane sheets (thickness 0.8 mm) purchased from
American Polyﬁlm Inc. (Branford, CT).
2.2. NP Synthesis. 2.2.1. OA-Capped NP Synthesis.
ZnMgO (10% Mg) and MgO NPs capped with OA were
synthesized using a previously adapted method from Park et
al.39 Zinc(II) chloride (10 mmol, 1.36 g) and sodium oleate (20
mmol, 6.08 g) were added to a solvent mixture of ethanol,
hexane, and deionized water (60 °C, 4 h) to produce zinc
oleate. Sodium chloride was washed and removed, and the
remaining organic layer was dried in vacuo to remove hexane,
yielding zinc oleate as a white solid. Magnesium oleate was
synthesized using the same procedure, with magnesium(II)
chloride as the precursor. Zinc oleate (0.9 g), magnesium oleate
(0.1 g), and OA (0.1784 mL) were dissolved in 1-octadecene
(20 mL) and stirred at room temperature. The reaction mixture
was heated to 320 °C under nitrogen (at a rate of 3.3 min−1)
and then held at 320 °C for 60 min. The resulting solution was
allowed to cool, and the particles were precipitated with ethanol
(80 mL). The solution was centrifuged, forming a solid
precipitate (20 °C, 504g, 6 min), and the supernatant was
discarded. The remaining solid precipitate was suspended in
hexane (30 mL), producing a suspension of ZnMgO NPs. MgO
NPs were synthesized via the same method by adding
magnesium oleate (1.0 g) to OA and 1-octadecene and heating
to 320 °C.
2.2.2. DOPA-Capped NP Synthesis. ZnO_DOPA NPs were
synthesized as previously reported by Brown et al.40 Brieﬂy
ZnEt2 and 0.2 equiv of DOPA are dissolved in toluene, and to
this a 0.4 M solution of water (in excess, 2 equiv used) in
acetone is added dropwise to hydrolyze the organometallic
reagent. Acetone is then added to precipitate the formed NPs,
which are centrifuged, washed further with acetone, and left to
air-dry overnight. To incorporate Mg, a mixture of ZnEt2 and
Mg(sec-Bu)(n-Bu) (0.7 M solution in hexane) was hydrolyzed
with the ligand using the same synthetic protocol. A 9:1 ratio of
Zn (300 mg, 2.43 mmol ZnEt2) and Mg (268 mg 0.7 M
solution, 0.27 mmol Mg(sec-Bu)(n-Bu)) reagents generated the
desired 10% Mg doping level.
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3. METHODS
3.1. Material Preparation. Swelling solutions for incorpo-
rating NPs into polyurethane were prepared by immersing 1
cm2 polymer squares into 1:1 hexane/DCM for OA-capped
NPs and toluene for DOPA-capped NPs. A NP concentration
of 1 mg/mL was used in both cases. The polymer samples were
left to swell-encapsulate for 24 h and then dipped into 0.001 M
aqueous solution of CV in water for 72 h (dark conditions). For
the antibacterial investigation, control samples (only solvent
treated) and polymer samples containing only NPs or CV were
prepared.
3.2. Microbiology Assay. The following 1 cm2 polyur-
ethane samples were used: (1) solvent-treated sample
(control), (2) NP-encapsulated polymer (MgO_OA,
ZnMgO_OA, ZnMgO_DOPA, and ZnO_DOPA), (3) CV-
coated polymer and (4) NP-encapsulated and CV-coated
polymer (CVMgO_OA, CVZnMgO_OA, CVZnMgO_DOPA,
and CVZnO_DOPA). The antibacterial activities of these
samples were tested against those of E. coli ATCC 25922, S.
aureus 8325-4,41 and an epidemic strain of MRSA (EMRSA-16;
S. aureus NCTC 13143), which is representative of one of the
two types of methicillin-resistant S. aureus strains that dominate
in UK hospitals.42 These organisms were stored at −70 °C in
Brain−Heart-Infusion broth (BHI; Oxoid) containing 20% (v/
v) glycerol and propagated onto either MacConkey agar
(Oxoid) in the case of E. coli or mannitol salt agar (Oxoid) in
the case of MRSA for a maximum of two subcultures at
intervals of 2 weeks.
The BHI broth was inoculated with one bacterial colony and
cultured in air at 37 °C for 18 h, with shaking at 200 rpm. The
bacterial pellet was recovered by centrifugation (20 °C ,
2867.2g, 5 min), washed in phosphate-buﬀered saline (PBS)
(10 mL), and centrifuged again to recover the pellet (20 °C,
2867.2g, 5 min), and the bacteria were ﬁnally resuspended in
PBS (10 mL). The washed suspension was diluted 1000-fold to
achieve an inoculum of ∼106 cfu/mL. In each experiment, the
inoculum was conﬁrmed by plating 10-fold serial dilutions on
agar for viable counts. Triplicates of each polymer sample type
were inoculated with 25 μL of the inoculum and covered with a
sterile coverslip (2.2 cm2). The samples were then irradiated for
up to 6 h using either (a) a white-light source (General Electric
28 W Watt Miser compact ﬂuorescent lamp) emitting an
average light intensity of 6600 lx or (b) a white-light source
used for general laboratory usage, emitting an average light
intensity of 500 lx. A further set of samples was incubated in the
dark for the same irradiation time.
After incubation, the inoculated samples and coverslips were
added to PBS (450 μL) and mixed using a vortex mixer. The
neat suspension and 10-fold serial dilutions were plated on agar
for viable counts and incubated aerobically at 37 °C for 24 h (E.
coli) or 48 h (S. aureus). The experiment was repeated three
times, and the statistical signiﬁcance of the following
comparisons was analyzed using the Mann−Whitney U test:
(1) control (polymer only) versus inoculum, (2) CV or NP
versus control, (3) CV and NP versus CV alone.
4. RESULTS AND DISCUSSION
4.1. NP Synthesis and Characterization. Oleate-capped
NPs were synthesized via a thermal decomposition method
adapted from Park et al.39 Metal oleate complexes were
prepared by a salt metathesis reaction of a metal chloride and
sodium oleate and heated up to 320 °C. Magnesium chloride
was used instead of zinc chloride to synthesize magnesium
Figure 1. TEM images of (a, b) MgO NPs and (c, d) ZnMgO NPs.
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oleate for MgO NPs, and a 9:1 ratio of zinc oleate and
magnesium oleate was used to synthesize ZnMgO NPs. TEM
images (Figures 1 and 2) and energy-dispersive X-ray (EDX)
spectra were recorded, illustrating the discrepancies between
the size and morphology of the NPs, despite having been
synthesized using the same method. The MgO NPs were
irregular in shape and formed clusters of up to 200−300 nm in
diameter. TEM images of ZnMgO showed monodispersity,
forming hexagonal truncated triangular plates (15 nm in
average diameter size). The EDX spectra showed that the
elemental composition of ZnMgO produced desired ratios well
within the error limits, but the presence of magnesium in MgO
NPs was diﬃcult to detect (Figure S1, Supporting Informa-
tion). XRD revealed a single phase for the doped ZnMgO NPs,
corresponding to Wurtzite ZnO, suggesting that the Mg is
intimately doped within the lattice, with no indication of a
secondary phase (Figure S5). Analysis of the linewidths of the
diﬀraction peaks using the Scherrer equation deﬁned ZnMgO
crystallites to have sizes of 5−10 nm, slightly smaller than those
observed by TEM. It is possible that the larger particles
observed by microscopy are made up of clusters of smaller
crystallites.
On the basis of a Tauc plot (Figure S2), the band onset of
oleate-capped ZnMgO NPs suspended in hexane was estimated
to be 3.34 eV (similar to that of bulk ZnO, 3.3 eV), indicating
that ZnMgO NPs are likely to act as UV-activated photo-
catalysts (<385 nm) and therefore should not exhibit signiﬁcant
white-light-activated bactericidal activity. As MgO NPs typically
absorb at <159 nm, which is within the region that a solvent
absorbs strongly in, it was not possible to determine the band
gap of the oleate-capped MgO NPs suspended in hexane.
DOPA-capped NPs were synthesized by a method adapted
by Brown et al.,22,40 that is, by the controlled hydrolysis of
ZnEt2 in the presence of 0.2 equiv of DOPA. Likewise, DOPA-
capped ZnMgO NPs were synthesized by hydrolyzing a 9:1
ratio of ZnEt2 and MgBu2 with the ligand. The sizes of the
particles were determined from the XRD spectra (Figures S5−
S7) using the Scherrer equation and gave estimated diameters
of 2.2 (±0.3) and 2.8 (±0.2) nm for the ZnO and ZnMgO
samples, respectively. The Mg-doped sample showed only one
phase in the XRD spectrum, corresponding to Wurtzite ZnO;
this gives us conﬁdence that the Mg is well doped within the
ZnO lattice. Inductively coupled plasma optical emission
spectroscopy (ICP-OES) was used to conﬁrm a 9:1 ratio of
Zn/Mg in the doped sample. UV spectroscopy allows the
determination of the band gap of these particles, with estimated
band gaps of 3.7 (±0.1) and 3.6 (±0.1) eV, respectively
(Figures S3 and S4).
4.2. Material Synthesis and Characterization. NPs were
impregnated into medical-grade polyurethane (1 cm2
squares).19−22 Optimal incorporation of the NPs throughout
the substrate was achieved by immersing the polymer squares
in the NP swelling solutions for 24 h. A 1:1 ratio of hexane/
DCM was used to encapsulate oleate-capped NPs, and toluene
was used to swell-encapsulate DOPA-capped ZnO NPs into the
polymer. The NP-incorporated polymers were subsequently
dipped in a CV solution (0.001 M in distilled water, 72 h),
resulting in polyurethane incorporating the following anti-
microbial combinations:
(a) CV- and OA-capped metal oxide NPs: CVMgO_OA,
CVZnMgO_OA, and CVZnO_OA.1
(b) CV- and DOPA-capped metal oxide NPs: CVZnMgO_-
DOPA and CVZnO_DOPA.
The modiﬁed polyurethane samples were analyzed using
UV−vis absorbance spectroscopy. Because of the low
concentration of NPs encapsulated in the polymer samples,
no characteristic UV−vis absorption peaks in the visible region
were observed. CV-coated polyurethane showed an absorbance
maximum at λ = 590 nm, with a shoulder peak at λ = 548. The
addition of NPs increased both the intensity and breadth of the
CV peak for CVZnO_OA and CVZnO_DOPA samples. This
trend continued for CVZnMgO_OA and CVZnMgO_DOPA,
and for CVMgO_OA, the absorption reached its maximum.
This was expected, as CVMgO_OA was darker in color than
any other sample (Figure S8).
X-ray photoelectron spectroscopy (XPS) was used to
determine whether the NPs were localized at the polymer
surface or encapsulated throughout the bulk (Figure S9). XPS
of CVZnMgO_OA did not show evidence of Mg (1s);
however, a weak Mg peak was observed at 1304.0 eV for the
CVMgO_OA sample. Notably, XPS has a detection limit of
∼0.1 atom %, indicating that MgO was present at a low
concentration, correlating with the EDX data. XPS showed the
presence of zinc on the surface of CVZnMgO_OA, with a
doublet in the Zn (2p) region indicating Zn in ZnO. The XPS
depth proﬁle data demonstrated a decrease in zinc content
within the polymer bulk. Peaks in the C (1s) region, N (1s)
region, and O (1s) region were observed in the control and
metal oxide NP-incorporated samples. A doublet in the Zn (2p)
region was also indicated on the surface and within the polymer
substrate for CVZnO_DOPA and CVZnMgO_DOPA. A peak
in the Mg (1s) region was present for CVZnMgO_DOPA
within the polymer substrate, but there was little indication of
Mg (1s) present on the surface of the polymer.
Static equilibrium water contact measurements (∼5.0 μL) of
all samples tested for antibacterial activity were recorded under
standard laboratory conditions (Table S1). The results showed
negligible diﬀerences between the hydrophobicities of the
untreated and modiﬁed polyurethane samples (varying ±8° in
contact angle). The photostability of CV, CVZnO_DOPA, and
CVZnMgO_DOPA samples was examined with an ∼3880 lx
white-light source for up to 60 days (Figure S10). UV−vis
spectroscopy showed that CVZnO_DOPA and CVZnMgO_-
DOPA were photostable over a 60 day period, demonstrating
29 and 31% photodegradation, respectively, compared to that
of CV (38%). This suggests that the materials are likely to
exhibit long-term photostability under standard lighting within
healthcare environments.
To encapsulate the NPs into polymers, certain solvents can
be used to induce polymer swelling, such that NPs can diﬀuse
Figure 2. Diagram illustrating ZnO NPs capped with (a) OA and (b) DOPA.
ACS Omega Article
DOI: 10.1021/acsomega.6b00017
ACS Omega 2016, 1, 334−343
337
through the polymer matrix.43 In this investigation, the NPs
used were dispersed in diﬀerent solvents: hexane for the oleate-
capped NPs and toluene for the DOPA-capped NPs.
Consequently, swelling measurements were conducted to
ensure that in both cases the polymers swelled to the same
extent. Immersion of the polymer samples in the DOPA-
capped NP/toluene suspension for 24 h resulted in a 142%
increase in the polymer size. In contrast to toluene, hexane is a
poor solvent for polymer swelling and thus the oleate-capped
NP swelling solution was optimized to a 1:1 ratio of hexane/
DCM such that comparable swelling was achieved. This
optimization should minimize diﬀerences in the concentrations
of encapsulated NPs induced by polymer swelling. Additionally,
a higher ratio of DCM compared to that of hexane (7.5:2.5)
resulted in deformation of the polymer samples after swell-
encapsulation; therefore, it was necessary to use a swelling
solution that did not alter the appearance and properties of the
sample for control purposes.
4.3. Microbiological Investigation. 4.3.1. Oleate-Cap-
ped NPs. The antibacterial activity of the oleate-capped NP-
encapsulated polyurethane samples was tested against S. aureus
8325-441,42 and E. coli ATCC 25922 as representative Gram-
positive and Gram-negative bacteria, respectively (Figures 3
and 4), using a protocol described by Sehmi et al.20 The
bactericidal eﬀects of the following polyurethane samples were
tested: (1) control polymer, (2) CV-coated polymer (CV), (3)
metal oxide NP-encapsulated polymers (MgO_OA,
ZnMgO_OA, ZnO_OA), and (4) CV-coated and metal
ox ide NP-encapsu la ted po lymers (CVMgO_OA,
CVZnMgO_OA, CVZnO_OA). The samples were exposed
to a white-light source, emitting an average light intensity of
6600 ± 900 lx at a distance of 25 cm from the samples, for up
to 4 h. A further set of samples was tested in the dark for the
same time periods. For completeness, the photobactericidal
activity of the MgO_OA and ZnMgO_OA samples synthesized
in this study are compared to that of ZnO_OA and
CVZnO_OA previously described by Sehmi et al. (Figures 3
and 4).20
Figure 3a illustrates the bactericidal activity of all of the
samples tested against S. aureus 8325-4 following 1 h of
incubation in the dark. Only samples containing combinations
of NPs and dye resulted in signiﬁcant killing of S. aureus 8325-4
(∼1.5 log; P = 0.002). However, after 1 h of white-light
exposure (Figure 3b), CV and CVMgO_OA resulted in an ∼2
log reduction in S. aureus 8325-4. CVZnMgO_OA and
CVZnO_OA samples caused complete killing, with
Figure 3. Viable counts of S. aureus 8325-4 after incubation at 20 °C on modiﬁed polyurethane squares for (a) 1 h in the dark and (b) 1 h with
exposure to white-light illumination with an average light intensity of 6600 ± 900 lx at a distance of 25 cm from the samples. *Bacterial counts were
reduced to below the detection limit of 100 cfu/mL. OA indicates NPs synthesized with OA capping. Error bars are based on the standard deviations
of three experimental replicates.
Figure 4. Viable counts of E. coli ATCC 25922 after incubation at 20 °C on modiﬁed polyurethane squares for (a) 4 h in the dark and (b) 2 h with
exposure to white-light illumination with an average light intensity of 6600 ± 900 lx at a distance of 25 cm from the samples. *Bacterial counts were
reduced to below the detection limit of 100 cfu/mL. OA indicates NPs synthesized with OA capping. Error bars are based on the standard deviation
of three experimental replicates.
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CVZnO_OA reducing the bacterial numbers to below the
detection limit (P = 0.002). Within 2 h of incubation,
CVMgO_OA, CVZnMgO_OA, and CVZnO_OA samples all
demonstrated highly signiﬁcant bactericidal activity against S.
aureus 8325-4 (≥4 log reduction; P = 0.002), under both white-
light and dark conditions (Figure S11). Moreover, irradiated
CV-coated samples also reduced S. aureus 8325-4 levels to
below the detection limit within this time period.
These samples were subsequently tested against E. coli
ATCC 25922 (Figure 4), and it was found that within 2 h the
CV sample achieved an ∼0.5 log reduction in bacterial numbers
under white-light activation. The presence of NPs enhanced
this eﬀect, with the CVZnMgO_OA sample resulting in a 1 log
reduction in bacterial numbers and CVZnO_OA achieving a
2.5 log reduction (P = 0.002). Incubation in the dark for 4 h
resulted in considerable activity against E. coli ATCC 25922,
with bacterial numbers reduced to below the detection limit
with the CVZnO_OA sample (Figure 4b). Note that 4 h of
irradiation of all CV-incorporated samples resulted in potent
photobactericidal activity (≥4 log; P = 0.002).
4.3.2. DOPA-Capped NPs. The bactericidal properties of the
polyurethane samples encapsulated with DOPA-capped ZnO
and ZnMgO NPs were also tested against E. coli. However, in
this case the activities of the samples were enhanced using a
low-intensity white-light source (500 ± 300 lx), comparable to
the dim lighting in a hospital environment, which can range
from 10 000 to 200 lx.44 The polymer squares were exposed to
ambient laboratory lighting conditions on a laboratory bench.
To test the materials using conditions close to the real-world
situation in other respects, the bacterial suspension in contact
with the material was not covered with a coverslip and the
samples were not placed in a humidity chamber. We have used
coverslips previously to ensure close, uniform contact between
the bacteria and the hydrophobic polymer surface, and a
humidity chamber was used to prevent evaporation. It should
be noted that in the absence of a coverslip there was no visible
evidence that the bacterial suspension dried up over the course
of the experiment.
The photobactericidal properties of the following polyur-
ethane samples were tested: (1) control polymer, (2) CV-
coated polymer (CV), (3) NP-encapsulated polymers
(ZnMgO_DOPA, ZnO_DOPA), and (4) CV- and NP-
encapsulated polymers (CVZnMgO_DOPA, CVZnO_DOPA).
As the MgO_OA polyurethane sample did not eﬀectively
reduce bacterial numbers, DOPA-capped MgO NPs were not
synthesized or tested for antibacterial activity. DOPA-capped
ZnO NPs and DOPA-capped-ZnMgO NPs were much smaller
in size than the corresponding oleate-capped NPs (2−4 nm
compared to 15−18 nm).
In the dark (Figure 5a), no bactericidal activity was detected
for the control sample, CV-coated polyurethane, and
ZnMgO_DOPA-encapsulated polyurethane when incubated
with E. coli ATCC 25922 for 2 h. However, within 3 h in the
dark (Figure 5c), a signiﬁcant reduction in bacterial numbers
(∼2 log; P = 0.002) was noted for the ZnO_DOPA samples on
their own, with an ∼0.5 log enhancement in bactericidal activity
upon incorporation of CV (2.5 log, CVZnO_DOPA sample).
The ZnMgO sample CVZnMgO_DOPA, however, showed a
comparatively reduced activity, with an ∼1 log reduction in
bacterial numbers (P = 0.002) in the dark. Irradiation of the CV
Figure 5. Viable counts of E. coli ATCC 25922 after incubation at 20 °C on modiﬁed polyurethane squares for (a) 2 h in the dark, (b) 2 h with
exposure to standard laboratory white light (500 ± 300 lx), (c) 3 h in the dark, and (d) 3 h with exposure to standard laboratory white light (500 ±
300 lx). *Bacterial counts were reduced to below the detection limit of 100 cfu/mL. DOPA indicates NPs synthesized with DOPA capping. Error
bars are based on the standard deviations of three experimental replicates.
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samples using standard laboratory lighting for 2 h (Figure 5b)
resulted in some photoactivated antibacterial activity (∼0.7 log
reduction), whereas the ZnO_DOPA samples showed similar
antibacterial eﬃcacies under light and dark conditions after 2 h
(∼2 log reduction). These ﬁndings suggest that the bactericidal
mechanism of the ZnO_DOPA sample is via a non-
photoactivated route, for example, absorption by the bacteria
or coordination of the bacteria to the ZnO surface. The
CVZnMgO_DOPA and CVZnO_DOPA samples induced
lethal photosensitization of E. coli ATCC 25922; the former
resulted in a 2 log reduction (P = 0.002), whereas the latter
reduced the bacterial numbers to below the detection limit (≥4
log; P = 0.002) within 3 h of irradiation.
These samples incorporated with NPs and dye were also
tested against an epidemic strain of MRSA (EMRSA-16; S.
aureus NCTC 13143) using white-light irradiation (∼500 lx).
These samples were not placed in a humidity chamber, and no
coverslip was used, to mimic the conditions of real-world
exposure. In the dark, only the CVZnO_DOPA and
CVZnMgO_DOPA samples demonstrated bactericidal activity
against S. aureus NCTC 13143 (∼1 log; P = 0.002; Figure 6a).
The ZnMgO_DOPA, ZnO_DOPA, and CV samples showed
limited photoactivated antimicrobial activities, reducing the
numbers of S. aureus NCTC 13143 by 0.4 log, 0.6 log, and 0.8
log, respectively, within 2 h of white-light irradiation (500 lx;
Figure 6b). However, the CV−NP combinations demonstrated
enhanced photobactericidal activities: CVZnMgO_DOPA
caused a 2 log reduction in the numbers of S. aureus NCTC
13143 (P = 0.002), whereas the CVZnO_DOPA sample was
the most eﬃcacious and reduced the bacterial numbers to
below the detection limit (≥4 log; P = 0.002).
These results demonstrate the increased eﬃcacy of ZnO NPs
(both DOPA-capped and oleate-capped) when combined with
CV, compared to that of MgO or ZnMgO. Note that two
methods for Mg doping of ZnO were attempted, and neither
achieved enhanced antibacterial activity compared to that of
ZnO. Moreover, ZnO_DOPA-encapsulated polyurethane
demonstrated the highest bactericidal activity against E. coli
ever reported for ZnO-incorporated materials (with and
without white-light activation) (Figure 4c,d). This may be
attributed to the small size of ZnO_DOPA NPs (∼2−4 nm)
compared to that of ZnO_OA NPs (∼18 nm). Previous studies
have shown that smaller NPs are more eﬀective at reducing the
numbers of E. coli.30 This is presumably accounted for by the
easier penetration of small NPs through the cytoplasmic
membrane of bacteria, enabling them to reach targets in the
cytoplasm.45,46
4.3.3. Comparison between DOPA- and OA-Capped
ZnMgO NPs. Additional experiments were carried out to
evaluate the antibacterial activity of CVZnMgO_DOPA against
S. aureus 8325-4 and E. coli ATCC 25922 at a range of light
intensities and incubation periods (Table 1). Both the
CVZnMgO_DOPA and CVZnMgO_OA samples achieved a
3 log reduction against S. aureus 8325-4 within 1 h of ∼6600 lx
white-light exposure. However, in the dark, within the same
time period, CVZnMgO_DOPA does not demonstrate any
signiﬁcant antibacterial activity, whereas CVZnMgO_OA
samples reduce the bacterial numbers by ∼1.5 log. Moreover,
on incubation for 2 h in the dark, the CVZnMgO_OA sample
reduces the bacterial numbers to below the detection limit,
compared to the CVZnMgO_DOPA sample, which only causes
a 0.5 log reduction in S. aureus 8325-4 numbers (Figure S10).
Table 1b summarizes the performance of CVZnMgO
samples when tested against E. coli ATCC 25922 under
diﬀerent lighting and incubation conditions. Both
CVZnMgO_DOPA and CVZnMgO_OA demonstrate similar
antibacterial eﬃcacies in the dark within 4 h. This is
unsurprising, as it has been previously noted that OA-capped
NPs enhance bactericidal activity in the dark when tested
against E. coli ATCC 25922.47 However, distinct diﬀerences in
the antibacterial performance were observed upon 2 h of white-
light exposure, where the CVZnMgO_DOPA sample reduced
Figure 6. Viable counts of EMRSA-16 after incubation at 20 °C on modiﬁed polyurethane squares for (a) 2 h in the dark and (b) 2 h with exposure
to standard laboratory white light (500 ± 300 lx). *Bacterial counts were reduced to below the detection limit of 100 cfu/mL. DOPA indicates NPs
synthesized with DOPA capping. Error bars are based on the standard deviations of three experimental replicates.
Table 1. Summary of the Antibacterial Activity of
CVZnMgO_DOPA against (a) S. aureus 8325-4 and (b) E.
coli ATCC 25922a
time (h) dark 500 ± 300 lx 6600 ± 900 lx
(a) S. aureus
6 1 log ≥4 log ≥4 log
4 1 log 3 log ≥4 log
2 0.5 log 1 log ≥4 log
1 no kill no kill 3 log
(b) E. coli
6 1 log ≥4 log ≥4 log
4 0.5 log 3 log ≥4 log
2 no kill 1 log 2 log
aAfter various incubation times in the dark and on exposure to
standard laboratory lighting (500 ± 300 lx) and a white-light source
emitting 6600 ± 900 lx.
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E. coli numbers twice as eﬀectively as the CVZnMgO_OA
sample.
These results suggest that the capping ligand plays a crucial
role in the bactericidal activity against Gram-positive bacteria,
such that CV samples containing oleate-capped ZnMgO NPs
are more eﬃcacious than those containing equivalent DOPA-
capped NPs. This enhanced activity may be attributed to the
bactericidal properties of the oleate ligand itself. Similar
bactericidal activities in the dark were observed by Noimark
et al. for TiO2
−- and Au/TiO2
−-encapsulated silicone
samples.47 Here, the NPs were capped with OA, which has
been observed to inhibit the growth of Gram-positive bacteria,
such as S. aureus.47 CVZnO_DOPA and ZnO_DOPA
displayed greater antibacterial activity against E. coli and
MRSA than CVZnMgO_DOPA and ZnMgO_DOPA under
the light and dark conditions (Figure 5). However, the
ZnO_DOPA and ZnMgO_DOPA samples displayed similar
levels of Zn2+ leaching (Table S2), which indicates that leaching
is not entirely responsible for the observed bactericidal activity
in the dark. Additionally, ZnMgO_OA and ZnMgO_DOPA
demonstrated similar levels of Zn2+ and Mg2+ leaching (Table
S2), yet CVZnMgO_OA and CVZnMgO_DOPA exhibited
diﬀerent bactericidal activities against S. aureus 8325-4 after 1 h
(∼1.5 log reduction and no reduction in bacteria, respectively).
Thus, the minimal amounts of leaching that occur from the
modiﬁed polymer samples are not responsible for their
antibacterial activities.
MgO-incorporated polyurethane exhibited poor activity
against both bacteria. However, CVMgO-incorporated samples
were eﬀective against S. aureus 8325-4. This provides further
evidence to suggest that the OA-capped agent is able to kill S.
aureus 8325-4 when combined with CV, as no bactericidal
activity was observed against E. coli ATCC 25922 on using
CVMgO_OA under light or dark conditions within 2 h (Figure
S12). We have shown that the addition of Mg as a dopant to
ZnO NPs is detrimental to their antibacterial activity; further
studies are underway to probe the surface and electronic
properties of ZnMgO_DOPA NPs to attempt to understand
the eﬀect of this added Mg.
Polyurethane encapsulated with DOPA-capped NPs was
tested against an epidemic strain of MRSA (EMRSA-16; S.
aureus NCTC 13143) that is rife in hospitals throughout the
United Kingdom.41,42,48 To mimic more closely the conditions
of natural exposure of the bacteria to the material, the
experiment was carried out without using a coverslip or a
humidity chamber. The CVZnO_DOPA sample induced lethal
photosensitization of S. aureus NCTC 13143, resulting in a ≥4
log reduction in the bacterial numbers, whereas CVZnMgO_-
DOPA achieved an ∼2.5 log reduction within 2 h of irradiation.
This article presents a detailed study on the eﬀects of the
presence of CV, NP size, NP-capping ligand, Mg doping, and
light intensity conditions on the antibacterial activity of
polyurethane. Doping of ZnO with Mg did not result in an
enhancement of the antibacterial activity under either light or
dark conditions when the samples were tested against both
Gram-positive and Gram-negative bacteria. In line with the
previous literature,30,31,49−51 the greatest bactericidal activity
was exhibited when smaller NPs were used. However, when the
NPs were incorporated with CV, the antibacterial activity of the
samples could be further enhanced by tuning the NP capping
group. Modiﬁcation of the NP surfaces with diﬀerent capping
agents can alter their toxicities, causing diﬀerences between
ROS generation and Zn2+ release.
The possible mechanisms for the antibacterial activity of
ZnO NPs include ROS formation and oxidative stress,20 Zn2+
release,30 electrostatic interaction,23,30 and internalization of the
NPs into the bacteria.23 Bacterial cell walls have an overall
negative charge, which facilitates electrostatic interactions
between the bacteria and CV and Zn2+ on the surface of the
polymer, assisting in bacterial killing. In this study, diﬀerences
in the antibacterial activities of ZnO-incorporated samples were
apparent between Gram-positive and Gram-negative bacteria,
presumably as a result of diﬀerences in the cell-wall structures:
Gram-positive bacteria have a thick peptidoglycan layer (20−80
nm), whereas Gram-negative bacteria have a thinner layer of
peptidoglycan (7−8 nm) and a second outer membrane.52 In
keeping with previous studies,18−22,42,51 Gram-negative bacteria
were found to be less susceptible to dye- and NP-incorporated
polymeric surfaces. This may be due to the reduced penetration
of radicals through the double cell membrane of Gram-negative
bacteria. Further studies will focus on testing the antibacterial
activities of these surfaces against more strains to understand
the diﬀerences between bacterial reduction of Gram-positive
and Gram-negative bacteria. It is possible that the smaller NPs
are able to penetrate through the bacterial cell wall more
eﬀectively than the larger 15−18 nm NPs. The fact that
polyurethane containing ZnO_DOPA, which is only 3 nm in
size, shows antibacterial activity under light and dark conditions
without CV (Figures 5 and 6) supports this argument. The
killing by ZnO_DOPA observed in the dark also suggests that
nonphotoactivated bactericidal activity occurs, either because
NPs penetrate into the bacterial cells or because they produce
ROS by interacting with defects on the polymer surface.
Further tests were performed to examine whether the amount
of ZnO NP leaching (shown in Table S2) was suﬃcient to
reduce the bactericidal activity of ZnO_DOPA. The samples
were immersed in water for 48 h and then removed and tested
against E. coli ATCC 25922. The antibacterial activity of
ZnO_DOPA did not diﬀer under the light or dark condition
after immersion in water (data not shown), which indicates that
leaching of the ZnO NPs is not suﬃcient to reduce the
bactericidal activity of the polymer. Zinc leaching is shown to
tail oﬀ over time, as all “loose” Zn is lost, which is also shown
by Noimark et al.22
Typically, ZnO NPs have a wide band gap (3.53 eV for
DOPA-capped ZnO),22 requiring UV illumination for ROS
generation. However, because of the presence of pre-existing
surface defects on the NPs, gap states can produce ROS under
lower-energy-light illumination50 (i.e., visible light) and even in
the dark. Moreover, samples with combinations of NPs and CV
showed increased bactericidal activity in the dark. This may be
due to defects on the NP surface, in addition to the intrinsic
bactericidal properties of the dye itself. Previous studies have
shown that the incorporation of a combination of ZnO and CV
into polyurethane can enhance the antibacterial activity of the
dye via both type I and type II mechanistic pathways.20 It is
anticipated that these bactericidal surfaces will produce
photogenerated species that can oxidize organic contaminants
on the surface so that they maintain their bactericidal
properties. Additionally, bacterial resistance is unlikely to
occur as these surfaces operate via multiple attack mechanisms.
These polymers have demonstrated considerable antibacterial
activity against a higher bacterial load than that likely to occur
in a clinical setting: ∼1 × 105 cfu/cm−2 of bacteria used in this
investigation compared to ∼1 × 102 cfu/cm−2 found in
hospitals.22,53,54
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5. CONCLUSIONS
For the ﬁrst time, polymers containing NPs and dye were
tested against an epidemic isolate of MRSA (EMRSA-16; S.
aureus NCTC 13143) under laboratory lighting conditions
(∼13× less intense than the lighting conditions in previous
studies performed by our group). These experiments were
conducted on the bench, with no barrier (coverslip) between
the inoculum and the environment, to determine the eﬃcacy of
these antimicrobial polymers under conditions similar to those
found naturally. Oleate-capped NPs combined with CV are
biocompatible and highly eﬀective at reducing the numbers of
Gram-positive bacteria, possibly due to the antibacterial
properties of the oleate ligand itself. ZnO_DOPA (2−4 nm)
was able to reduce the numbers of E. coli without a need for a
photosensitizer or white-light activation. We observed highly
signiﬁcant bactericidal activity by CVZnO_DOPA against an
epidemic strain of MRSA. This study established polyurethane
incorporated with CV and ZnO or ZnMgO NPs as a highly
eﬀective antibacterial surface, under conditions that mimic
natural exposure in clinical environments. This technology
shows promise for use in hospitals to reduce bacterial surface
contamination and, ultimately, the risk for HCAIs.
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